JAZZ Stock Risk & Deep Value Analysis
Jazz Pharmaceuticals PLC
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About JAZZ Stock
We analyzed Jazz Pharmaceuticals PLC using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran JAZZ through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
JAZZ Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is that zanidatamab, while promising, fails to achieve regulatory approval, experiences significant launch delays, or underperforms commercial expectations, removing a key future growth driver from Jazz's portfolio and potentially dampening investor confidence.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Insider selling activity observed (6,000 shares on 03/03/2026 and proposed 6,000 shares on 04/01/2026), though not exceptionally large.
- ⚠
Net margin was negative (-8.35% in Q4 2025) due to GAAP net loss of $356M in FY2025 (likely impacted by litigation/acquisition, as operating margin improved).
Upcoming Risk Events
- 📅
Zanidatamab regulatory delay or rejection by FDA
- 📅
Failure to meet Q1 2026 earnings expectations
- 📅
Increased generic competition for high-sodium oxybate products
When to Reconsider
- 🚪
Sell if zanidatamab receives a complete response letter from the FDA (signaling rejection or major delay).
- 🚪
Exit if Xywav revenue shows significant decline (e.g., >10% YoY) for two consecutive quarters.
- 🚪
Sell if operating margins begin to consistently decline quarter-over-quarter despite revenue growth.
Unlock JAZZ Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Jazz Pharmaceuticals PLC (JAZZ) Do?
Market Cap
$11.95B
Sector
Healthcare
Industry
Biotechnology
Employees
2,800
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Visit Jazz Pharmaceuticals PLC WebsiteInvestment Thesis
Jazz Pharmaceuticals represents a stable, cash-generative specialty pharma company with an attractive valuation relative to its improving profitability and a significant near-term growth catalyst in zanidatamab. While not a 10x growth play, it offers a compelling combination of consistent revenue growth, strong free cash flow, and pipeline upside, making it a potentially solid performer within a diversified portfolio.
Is JAZZ Stock Undervalued?
Unlock the full AI analysis for JAZZ
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
JAZZ Price Targets & Strategy
12-Month Target
$223.50
Bull Case
$275.00
Bear Case
$170.00
Valuation Basis
Based on Street mean target; implies modest multiple expansion from current ~8x NTM earnings given pipeline catalysts.
Entry Strategy
Consider dollar-cost averaging on pullbacks towards the $185-$190 range, which could represent a retest of recent support or a more attractive entry given current analyst targets.
Exit Strategy
Consider profit-taking between $225-$235 (mean analyst target range) with a stop-loss order below $170 to limit downside exposure.
Portfolio Allocation
3-5% for moderate risk tolerance, reflecting its established but non-explosive growth profile.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is JAZZ Financially Healthy?
Valuation
P/E Ratio
-33.27
Forward P/E
8.34
EV/EBITDA
7.00
PEG Ratio
0.33
Price/Book
1.70
Price/Sales
1.70
Profitability
Gross Margin
88.21%
Operating Margin
-10.08%
Net Margin
-8.35%
Return on Equity
-8.82%
Revenue Growth
4.88%
EPS
$-5.85
Balance Sheet
Current Ratio
1.86
Quick Ratio
1.60
Debt/Equity
1.24
Total Debt
$5.32B
Cash Flow
Operating Cash Flow
$1.32B
Free Cash Flow
$1.34B
EBITDA
$1.61B
Other
Beta (Volatility)
0.25
Does JAZZ Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
Jazz's moat is primarily driven by its patented drug portfolio, which provides a period of exclusivity and pricing power. However, this moat is time-limited by patent expirations and vulnerable to the emergence of superior or more affordable treatments from competitors.
Moat Erosion Risks
- •Patent expirations for core products leading to generic competition (e.g., high-sodium oxybate threats).
- •Development of highly effective alternative therapies by competitors that reduce the need for Jazz's products.
JAZZ Competitive Moat Analysis
Sign up to see competitive advantages
JAZZ Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - No specific data available, but established pharma generally has less retail social media volatility unless major news breaks.
Institutional Sentiment
Positive - Analyst price targets indicate confidence, and Vanguard's Schedule 13G/A filing, while a realignment, points to ongoing institutional interest.
Insider Activity (Form 4)
An insider filed Form 144 on 04/01/2026 for a proposed sale of 6,000 shares. Prior to this, 6,000 shares were sold on 03/03/2026 for $1,118,613.32, including stock-option derived quantities. This indicates selling activity by insiders.
Options Flow
Normal options activity - No specific unusual options flow data was provided in the research.
Earnings Intelligence
Next Earnings
2026-05-05
Surprise Probability
Medium
Historical Earnings Pattern
Q4 2025 results showed a beat on both revenue and EPS, suggesting a potential positive reaction to future beats, though no consistent historical pattern was detailed.
Key Metrics to Watch
Competitive Position
Top Competitor
UCB
Market Share Trend
Stable to Gaining in its core therapeutic areas, particularly with Xywav showing strong growth.
Valuation vs Peers
Trading at a discount to many specialty pharma and oncology-focused biotech peers based on its forward P/E of ~8x NTM earnings, despite consistent profitability and pipeline progress.
Competitive Advantages
- •Patented drug portfolio (Xywav, Epidiolex, zanidatamab pending)
- •Established commercial infrastructure in neuroscience and oncology
- •Strong cash flow generation for R&D and M&A
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive JAZZ Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings on May 5, 2026
- •2026 AAN Annual Meeting presentations on Epidiolex and Xywav (April 18-22)
- •Potential FDA approval for zanidatamab (HER2+ GEA) in H2 2026
Medium-Term (6-18 months)
- •Commercial launch and ramp-up of zanidatamab
- •Label expansions for existing products (e.g., Epidiolex in LGS/DS/TSC)
- •Progress of Suvecaltamide (Phase 2 Parkinson's tremor) into later stages
Long-Term (18+ months)
- •Further pipeline advancements and new drug candidates entering late-stage trials
- •Strategic M&A to diversify or strengthen portfolio
- •Expansion into new geographic markets for key products
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for JAZZ?
- ✓
Successful and timely FDA approval and launch of zanidatamab
- ✓
Continued growth in Xywav and Epidiolex sales, outperforming market expectations
- ✓
Positive updates from other early-stage pipeline assets (e.g., Suvecaltamide)
Bull Case Analysis
See what could go right with Premium
Competing with JAZZ
See how Jazz Pharmaceuticals PLC compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Jazz Pharmaceuticals PLC JAZZ | $11.9B | 0.7 | -33.3 | $4.2B | -8.3% | 4.9% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Jazz Pharmaceuticals PLC Makes Money
Jazz Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing innovative medicines for people with serious diseases, often with limited or no therapeutic options. It generates revenue primarily by selling its pharmaceutical products, which target areas like sleep disorders (e.g., narcolepsy, idiopathic hypersomnia) and oncology (e.g., certain types of cancer). The company invests significantly in research and development to discover and advance new drug candidates, then commercializes them through its sales and marketing teams to healthcare providers globally.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Jazz Pharmaceuticals PLC (JAZZ)?
As of April 14, 2026, Jazz Pharmaceuticals PLC has a DVR Score of 0.7 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Jazz Pharmaceuticals PLC?
Jazz Pharmaceuticals PLC's market capitalization is approximately $11.9B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Jazz Pharmaceuticals PLC use?
JAZZ is the ticker symbol for Jazz Pharmaceuticals PLC. The company trades on the NMS.
What is the risk level for JAZZ stock?
Our analysis rates Jazz Pharmaceuticals PLC's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of JAZZ?
Jazz Pharmaceuticals PLC currently has a price-to-earnings (P/E) ratio of -33.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Jazz Pharmaceuticals PLC's revenue growing?
Jazz Pharmaceuticals PLC has reported revenue growth of 4.9%. The company is growing at a moderate pace.
Is JAZZ stock profitable?
Jazz Pharmaceuticals PLC has a profit margin of -8.3%. The company is currently unprofitable.
How often is the JAZZ DVR analysis updated?
Our AI-powered analysis of Jazz Pharmaceuticals PLC is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 14, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for JAZZ (Jazz Pharmaceuticals PLC) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.